Page 101 - 《中国药房》2021年07期

domised trial of a very-low-dose warfarin for prevention anticoagulant for the prevention of thrombosis in ambula-
of thromboembolism in stage Ⅳ breast cancer[J]. Lancet， tory patients with cancer：a systematic review and meta-
1994，343（8902）：886-889. analysis[J]. J Thromb Haemost，2019，17（12）：2141-2151.
[24] LEE A Y，LEVINE M N，BAKER R I，et al. Low-molecu- [36] COHEN A T，KATHOLING A，RIETBROCK S，et al. Epi-
lar-weight heparin versus a coumarin for the prevention of demiology of first and recurrent venous thromboembolism
recurrent venous thromboembolism in patients with can- in patients with active cancer：a population-based cohort
cer[J]. N Engl J Med，2003，349（2）：146-153. study[J]. Thromb Haemost，2017，117（1）：57-65.
[25] AKL E A，GUNUKULA S，BARBA M，et al. Parenteral [37] MARTINEZ C，COHEN A T，BAMBER L，et al. Epide-
anticoagulation in patients with cancer who have no thera- miology of first and recurrent venous thromboembolism：a
peutic or prophylactic indication for anticoagulation[J]. population-based cohort study in patients without active
Cochrane Database Syst Rev，2011（4）：CD006652. cancer[J]. Thromb Haemost，2014，112（2）：255-263.
[26] PALUMBO A，CAVO M，BRINGHEN S，et al. Aspirin， [38] RASKOB G E，VAN E S N，SEGERS A，et al. Edoxaban
warfarin，or enoxaparin thromboprophylaxis in patients for venous thromboembolism in patients with cancer：re-
with multiple myeloma treated with thalidomide：a phase sults from a non-inferiority subgroup analysis of the Hoku-
Ⅲ，open-label，randomized trial[J]. J Clin Oncol，2011，29 sai-VTE randomised，double-blind，double-dummy trial
（8）：986-993.
[J]. Lancet Haematol，2016，3（8）：e379-e387.
[27] AKL E A，KAHALE L，BARBA M，et al. Anticoagulation [39] AKL E A，KAHALE L A，HAKOUM M B，et al. Paren-
for the long-term treatment of venous thromboembolism
teral anticoagulation in ambulatory patients with cancer
in patients with cancer[J]. Cochrane Database Syst Rev，
[J]. Cochrane Database Syst Rev，2017，9（9）：CD006652.
2014（7）：CD006650.
[40] KAHALE L A，HAKOUM M B，TSOLAKIAN I G，et al.
[28] RASKOB G E，VAN ES N，VERHAMME P，et al. Edoxa-
Oral anticoagulation in people with cancer who have no
ban for the treatment of cancer-associated venous throm-
therapeutic or prophylactic indication for anticoagula-
boembolism[J]. N Engl J Med，2018，378（7）：615-624.
tion[J]. Cochrane Database Syst Rev，2017，12（12）：
[29] YOUNG A M，MARSHALL A，THIRLWALL J，et al.
CD006466.
Comparison of an oral factor Ⅹa inhibitor with low
[41] NOBLE S，MATZDORFF A，MARAVEYAS A，et al.
molecular weight heparin in patients with cancer with
Assessing patients’anticoagulation preferences for the
venous thromboembolism：results of a randomized trial
treatment of cancer-associated thrombosis using conjoint
（SELECT-D）[J]. J Clin Oncol，2018，36（20）：2017-2023.
methodology[J]. Haematologica，2015，100（11）：1486-
[30] LI A，GARCIA D A，LYMAN G H，et al. Direct oral anti-
1492.
coagulant（DOAC）versus low-molecular-weight heparin
[42] HUTCHINSON A，REES S，YOUNG A，et al. Oral anti-
（LMWH）for treatment of cancer associated thrombosis
coagulation is preferable to injected，but only if it is safe
（CAT） ：a systematic review and meta-analysis[J].
and effective：an interview study of patient and carer expe-
Thromb Res，2019，173：158-163.
rience of oral and injected anticoagulant therapy for can-
[31] CHEE C E，ASHRANI A A，MARKS R S，et al. Predic-
cer-associated thrombosis in the SELECT-D trial[J]. Palli-
tors of venous thromboembolism recurrence and bleeding
ative Med，2019，33（5）：510-517.
among active cancer patients：a population-based cohort
[43] 李京，王悦，宋玉娟，等. 首批低分子肝素相对分子质量
study[J]. Blood，2014，123（25）：3972-3978.
[32] CARRIER M，ABOU-NASSAR K，MALLICK R，et al. 国家对照品的建立[J]. 中国药学杂志，2020，55（10）：
Apixaban to prevent venous thromboembolism in patients 824-837.
with cancer[J]. N Engl J Med，2019，380（8）：711-719. [44] MCCART G M，KAYSER S R. Therapeutic equivalency
[33] KHORANA A A，SOFF G A，KAKKAR A K，et al. Riva- of low-molecular-weight heparins[J]. Ann Pharmacother，
roxaban for thromboprophylaxis in high-risk ambulatory 2002，36（6）：1042-1057.
patients with cancer[J]. N Engl J Med，2019，380（8）： [45] MAI V，TANGUAY V F，GUAY C A，et al. DOAC com-
720-728. pared to LMWH in the treatment of cancer related-venous
[34] AGNELLI G. Direct oral anticoagulants for thrombopro- thromboembolism：a systematic review and meta-analy-
phylaxis in ambulatory patients with cancer[J]. N Engl J sis[J]. J Thromb Thrombolysis，2020，50（3）：661-667.
Med，2019，380（8）：781-783. （收稿日期：2020-11-17 修回日期：2021-03-15）
[35] LI A，KUDERER N M，GARCIA D A，et al. Direct oral （编辑：胡晓霖）

中国药房 2021年第32卷第7期 China Pharmacy 2021 Vol. 32 No. 7 ·859 ·